XORTX Therapeutics, Inc. (XRTX)
1.06
0.00 (0.00%)
USD |
NASDAQ |
Oct 27, 16:00
1.06
0.00 (0.00%)
After-Hours: 20:00
XORTX Therapeutics Cash from Investing (Quarterly) : -0.1388M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.1388M |
| March 31, 2026 | -0.0079M |
| December 31, 2025 | -0.2644M |
| September 30, 2025 | -0.0055M |
| June 30, 2025 | -0.0223M |
| March 31, 2025 | -0.0034M |
| December 31, 2024 | -0.0033M |
| September 30, 2024 | -0.0231M |
| June 30, 2024 | -0.009M |
| March 31, 2024 | -0.0026M |
| December 31, 2023 | -0.0098M |
| September 30, 2023 | -0.0073M |
| June 30, 2023 | -0.0095M |
| March 31, 2023 | -0.0197M |
| December 31, 2022 | -0.016M |
| September 30, 2022 | -0.0058M |
| June 30, 2022 | -0.0215M |
| Date | Value |
|---|---|
| March 31, 2022 | -0.0026M |
| December 31, 2021 | -0.0135M |
| September 30, 2021 | -0.0098M |
| June 30, 2021 | -0.0084M |
| March 31, 2021 | -0.0001M |
| December 31, 2020 | -0.0022M |
| September 30, 2020 | -0.0035M |
| June 30, 2020 | -0.0026M |
| March 31, 2020 | -0.0024M |
| December 31, 2019 | -0.0001M |
| September 30, 2019 | -0.0028M |
| June 30, 2019 | -0.0024M |
| March 31, 2019 | 0.00 |
| December 31, 2018 | -0.003M |
| September 30, 2018 | -0.0068M |
| June 30, 2018 | 0.00 |
| March 31, 2018 | -0.1122M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Lexaria Bioscience Corp. | -0.0271M |
| InMed Pharmaceuticals, Inc. | 0.00 |
| Target Group, Inc. (Canada) | -0.0065M |
| NervGen Pharma Corp. | -0.0001M |
| Milestone Pharmaceuticals, Inc. | 111.84M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -3.250M |
| Cash from Financing (Quarterly) | 4.138M |
| Free Cash Flow | -5.239M |
| Free Cash Flow Per Share (Quarterly) | -2.097 |
| Free Cash Flow to Equity (Quarterly) | -3.378M |
| Free Cash Flow to Firm (Quarterly) | -3.393M |
| Free Cash Flow Yield | -373.5% |